Olumiant 2mg Tablet (baricitinib)

Olumiant 2mg Tablet (Baricitinib) contains Baricitinib 2mg. It is a jak1/jak2 inhibitor. Moderate-to-severe rheumatoid arthritis with inadequate response to appropriate therapies; severe alopecia areata in adults; certain hospitalized COVID-19 patients under specific protocols. Indication and dose differ by condition. Its mechanism is: Inhibits Janus kinase 1 and 2 signalling, reducing downstream inflammatory cytokine pathways.

Treatment requires a clinician to match the indication, dose, comorbidities, previous therapies and concurrent medicines. Clinical benefits and adverse effects are specific to the underlying disease and patient population. The exact product presentation should be confirmed against the commercial carton before publication.

Moderate-to-severe rheumatoid arthritis with inadequate response to appropriate therapies; severe alopecia areata in adults; certain hospitalized COVID-19 patients under specific protocols. Indication and dose differ by condition. Diagnosis, disease activity, prior treatment, infection status and organ function determine whether this medicine is appropriate. Not every indication has the same dosing schedule or evidence base.

Inhibits Janus kinase 1 and 2 signalling, reducing downstream inflammatory cytokine pathways. By altering the relevant inflammatory or infectious pathway, the medicine can improve disease-related outcomes when appropriately selected and monitored; it does not eliminate the need for ongoing disease assessment.

RA-BEAM and RA-BEGIN support rheumatoid arthritis efficacy; BRAVE-AA1/AA2 studied scalp-hair regrowth in severe alopecia areata. Outcomes are indication-specific. Study endpoints and effect sizes must be quoted only with the relevant trial, comparator, dose, time point and patient population; these should not be generalized across indications or attributed to a different commercial brand.

Common or clinically relevant effects include: Upper respiratory infection, nausea, herpes zoster, headache, acne or folliculitis (population-dependent). The likelihood of a particular event depends on indication, dose, treatment duration and other medicines. New, persistent or severe symptoms require medical review.

The doctor will decide the dose and duration of Olumiant 2mg Tablet (baricitinib) based on the disease condition and other factors such as body weight and age. Swallow the whole tablet with a glass of water, as it is an orally available drug. This tablet can be taken with or without food but at a fixed time every day to get better results. Take it exactly as advised by the doctor; don't miss a dose or overdose the medicine.

For tablets, take a missed dose when remembered unless it is close to the next scheduled dose; do not double. For scheduled biologic injections, contact the treatment team to agree on the next administration date. Follow the exact product leaflet for the prescribed indication.